Low risk for all-cause mortality among patients with lung neuroendocrine tumors co-diagnosed with pituitary adenomas

Naama Peltz-Sinvani, Ruth Percik, Inbal Uri, Sapir Kon Kfir, Amir Tirosh, Amit Tirosh*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose: Lung neoplasms often co-occur with pituitary adenoma (PA). However, whether co-diagnosis of lung neuroendocrine tumors (LNETs) and PA constitute a unique entity and the impact of such co-diagnosis on patients’ outcome is yet to be defined. The study objective was to compare patients’ clinical characteristics with LNET to patients co-diagnosed with PA. Methods: A Retrospective, case-control study based on the Surveillance, Epidemiology, and End Results (SEER) registry database between 2000 and 2016. A total of 2947 patients with LNET, including 2913 with LNET alone (“Sporadic”) and 34 patients with both LNET and PA (“LNET-PA”). Results: PA preceded LNET diagnosis in 85.3% of patients and had higher rates among LNET patients (34/2947) than with any cancer (p < 0.00001) and compared to patients with non-small cell lung cancer (NSCLC) (15/2378, p = 0.047). LNET-PA patients were younger at diagnosis compared with NSCLC patients and PA (p = 0.04). Among patients <60 years with LNET, co-diagnosis with PA was associated with lower all-cause mortality (ACM) risk (Log-rank test, p = 0.03). Adjusted ACM risk of patients with LNET-PA was lower than sporadic LNET (hazard ratio 0.553, 95% confidence interval 0.309–0.99, p = 0.046), especially among Caucasians, and lower overall-mortality risk in patients <60 years with borderline statistical significance (p = 0.071). Conclusions: Patients with both LNET and PA constitute a distinct morbidity and mortality profile than sporadic LNET, possibly suggesting an undefined MEN syndrome. Additional studies to further investigate patients’ natural course and genetic profile with these neoplasms are needed.

Original languageEnglish
Pages (from-to)745-751
Number of pages7
Issue number3
StatePublished - Sep 2021


  • Lung neuroendocrine tumor
  • MEN1
  • Mortality
  • Pituitary tumors


Dive into the research topics of 'Low risk for all-cause mortality among patients with lung neuroendocrine tumors co-diagnosed with pituitary adenomas'. Together they form a unique fingerprint.

Cite this